drugset / Trial / NCT01698866
Low Grade Lymphoma
NaSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to assess the seroconversion rate and the cellular immune response after vaccination against hepatitis B virus in patients with lymphoproliferative syndrome like chronic lymphocytic leukemia stade A and follicular lymphoma without of treatment criteria.
Timeline
- Start
- 2012-07
- Primary completion
- 2017-07
- Completion
- 2018-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GenHevac B Pasteur | Vaccine | 20 ug | — |